Jean-Philippe Tripet
Founder and Chairman @ Aravis Ventures
Jean-Philippe Tripet is a Series A investor at Aravis Ventures focused on Biopharma and Health Care. Jean-Philippe Tripet, managing partner and founder of Aravis, has over 15 years experience as portfolio manager and financial analyst. In 1994 he co-founded the Lombard Odier Immunology fund that became one of the most successful healthcare funds in Europe under his supervision. He has supervised over 70 private investments. Since 1994Jean-Philippe Tripet has participated actively to the launch and financing of many successful start-up companies such as Modex, Novimmune, Cytos, Genedata, Esbatech and Novalon. He is a member of the board of directors of Evolva, MerLion, Symetis Omeros, S Bio, TelorMedix and Synosia. He has a degree in business administration from the University of Geneva, did graduate studies in San Diego (USA) and is a Chartered Financial Analyst.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Jean-Philippe Tripet invests in
Stages Jean-Philippe Tripet invests in
Countries Jean-Philippe Tripet invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biopharma 1 (33%)
- Health Care 1 (33%)
- Therapeutics 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Telormedix
|
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $6.8M / Series B / Dec 02, 2013 | |
|
Telormedix
|
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $7M / Series B / Jan 25, 2012 | |
|
Telormedix
|
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $19M / Series A / Sep 30, 2008 |
Co-Investors
About Aravis Ventures
Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.
Aravis Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jean-Philippe Tripet
Founder and Chairman
|
|||
Andreas Jacobs
Managing Partner & CFO
|
|||
Kadri Vunder
Investment Manager
|
|||
Marc Krattinger
Partner
|
|||
Margaretha Bruelisauer
Accountant
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jean-Philippe Tripet invest in?
Jean-Philippe Tripet invests primarily in Biopharma, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jean-Philippe Tripet?
Public channels for Jean-Philippe Tripet include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jean-Philippe Tripet last invest?
The most recent investment recorded for Jean-Philippe Tripet closed in Dec 2013. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
